Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial
This study is an ongoing multicenter, randomized, controlled, open-label trial. A total of 150 patients with COPD, non-CF bronchiectasis or asthma, andP. aeruginosa-positive lower respiratory tract samples will be randomly assigned with a 1:1 ratio to either no antibiotic treatment or anti-pseudomonal antibiotic treatment with intravenous beta-lactam and oral ciprofloxacin for 14 days. The primary outcome, analyzed with two co-primary endpoints, is (i) time to prednisolone and/or antibiotic requiring exacerbation or death, in the primary or secondary health sector, within days 20 –365 from study allocation and (ii) days ...
Source: Trials - September 27, 2022 Category: Research Source Type: clinical trials
Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition
Condition: Healthy Subjects Interventions: Drug: Ciprofloxacin 750 mg; Drug: Ciproxin 750 mg Sponsor: Future University in Egypt Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2022 Category: Research Source Type: clinical trials
PLGA Nanoparticles Entrapping Ciprofloxacin to Treat E-Fecalis Infections in Endodontics
Condition: Bacterial Infections Oral Interventions: Device: Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels; Device: Ciprofloxacin paste and solution Sponsor: British University In Egypt Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2022 Category: Research Source Type: clinical trials
